Alprazolam
Viewing r1 — Apr 20, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Alprazolam — Xanax, bars, xans — is a synthetic depressant of the benzodiazepine class. It is a high-potency triazolobenzodiazepine, distinguished from diazepam by rapid onset and shorter duration.[1] Alprazolam is a positive allosteric modulator at GABA-A receptors,[2] producing its effects by amplifying the brain's primary inhibitory signaling.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
diazepam, clonazepam, lorazepam +5 morediazepam, clonazepam, lorazepam, triazolam, zolpidem, zopiclone, alcohol, barbiturates show less
Synthesized by Jackson B. Hester Jr. at the Upjohn Company in the late 1960s, alprazolam was approved by the FDA in 1981 for anxiety disorders. It became the most prescribed medication in the United States by 1983, driven by clinical utility in panic disorder and aggressive pharmaceutical marketing.[3] It remains one of the most widely prescribed and most frequently misused benzodiazepines worldwide.[4]
Subjective effects include anxiolysis, sedation, muscle relaxation, cognitive suppression, and disinhibition. The experience is defined by the speed of the shift — a rapid, perceptible transition from baseline anxiety to emotional quieting that users describe as distinctly reinforcing compared to longer-acting benzodiazepines.[5] Memory impairment, psychomotor slowing, and rebound effect anxiety between doses are characteristic unsought effects.
Alprazolam produces rapid physical dependence — within days of continuous use[6] — but carries a wide therapeutic index in isolation, with no fatalities from alprazolam alone documented.[7] The primary danger is combination with opioids or alcohol, where synergistic respiratory depression can be fatal even at subtherapeutic alprazolam concentrations;[8] abrupt discontinuation in dependent users risks seizures. Decades of clinical and epidemiological data support thorough understanding of alprazolam, though long-term cognitive consequences of chronic use remain unresolved.
History[edit]
Discovery
Alprazolam was synthesized by Jackson B. Hester Jr. at the Upjohn Company in Kalamazoo, Michigan, in the late 1960s. The compound emerged from a research program into triazolobenzodiazepines — a structural subclass featuring a fused triazole ring intended to enhance potency and improve the separation of anxiolytic from sedative effects. The U.S. patent was filed in 1969 and granted in 1976; it expired in September 1993, opening the door to generic production.[3]
Clinical Adoption
The FDA approved alprazolam on October 16, 1981, initially for generalized anxiety disorder, later expanding the indication to panic disorder with and without agoraphobia. Marketed as Xanax, it became the most prescribed medication in the United States by 1983[3] — a speed of commercial dominance reflecting both genuine clinical need and assertive pharmaceutical marketing. Upjohn was subsequently acquired by Pfizer; the Upjohn division later merged with Mylan to form Viatris.
Regulatory Response
Alprazolam was placed on Schedule IV of the U.S. Controlled Substances Act — a classification contested by clinicians who argue its rapid onset and short half-life confer higher abuse liability than other Schedule IV benzodiazepines. Australia took the most decisive action, reclassifying alprazolam to Schedule 8 (its highest-restriction prescription category) in February 2014, citing concerns over tolerance, dependence, and widespread misuse.[9] The country's Therapeutic Goods Administration does not recommend alprazolam for panic disorder.[3]
The brand name Xanax — coined by Upjohn's marketing division — became synonymous with benzodiazepine use in American popular culture. "Bars" refers to the distinctive scored shape of the 2 mg rectangular tablet, while "xannies" and "xans" entered widespread slang. In hip-hop and internet culture from the mid-2010s onward, alprazolam acquired a dual identity: both a symbol of anxiety-era self-medication and a cautionary substance linked to blackout behavior and impulsive decision-making.
Chemistry[edit]
Structural Class
Alprazolam belongs to the triazolobenzodiazepine subclass — benzodiazepines bearing a fused 1,2,4-triazole ring at positions 1 and 2 of the diazepine ring. This triazole fusion distinguishes it from classical 1,4-benzodiazepines such as diazepam and chlordiazepoxide, conferring higher potency per milligram and a shorter half-life. Structural analogs include triazolam (ultrashort-acting) and estazolam (lacking the methyl group at position 1).
Molecular Structure
| Molecular formula | C₁₇H₁₃ClN₄ |
| Molecular weight | 308.8 g/mol |
The core structure consists of a 1,4-benzodiazepine ring fused with a 1,2,4-triazole ring. Key features include a chlorine at position 8 — which forms a halogen bond with the receptor residue α1-His102, critical for binding[10] — a methyl group at position 1 of the triazole, and a phenyl ring at position 6.
Stereochemistry
Alprazolam lacks a chirality center and does not exist as optical isomers. Neither the triazolo ring fusion nor the benzodiazepine core contains an asymmetric carbon.inferred
Physical Properties
Alprazolam is a white crystalline solid with a melting point of 228–229.5°C.[11] It is virtually insoluble in water, soluble in alcohol, and freely soluble in chloroform.[12] Storage requires airtight containers protected from light at 2–8°C.
Pharmacology[edit]
Mechanism of Action
Alprazolam enhances the activity of GABA — the brain's primary inhibitory neurotransmitter — by binding an allosteric site on GABA-A receptors.[2] It does not activate these receptors directly; instead, it increases the frequency with which GABA opens chloride ion channels, amplifying inhibitory signaling only when GABA is already present.
The compound acts across multiple GABA-A receptor subtypes, which accounts for its broad effect profile: anxiolysis (primarily α2/α3 subtypes), sedation and seizure suppression (α1), and muscle relaxation (α2).[10] This non-selectivity means the therapeutic effect cannot be cleanly separated from sedation, cognitive impairment, and abuse liability.
A critical architectural detail: the γ2 subunit is required for alprazolam to bind at all. A single amino acid substitution in this subunit doubles alprazolam's effect, demonstrating that receptor structure — not ligand chemistry alone — determines the magnitude of modulation.[13]
Pharmacokinetics
Alprazolam is rapidly and nearly completely absorbed after oral administration, with bioavailability of 80–100% and peak plasma levels reached within 0.7–1.8 hours.[14] This fast absorption contributes directly to its reinforcing quality and to its abuse liability relative to slower-absorbing benzodiazepines.[1] Pharmacokinetics are linear across the therapeutic dose range.[15]
The liver metabolizes alprazolam primarily through the CYP3A4 enzyme, producing two minor active metabolites at less than 10% of parent drug levels.[15] The half-life of 9–16 hours positions it as short-to-intermediate acting among benzodiazepines.[14]
This relatively short half-life has a practical consequence: in dependent users, plasma levels drop fast enough between doses to trigger inter-dose withdrawal symptoms — a pattern less common with longer-acting benzodiazepines like diazepam.[5]
Neuroscience[edit]
Where It Acts
Alprazolam amplifies inhibitory signaling across the brain by potentiating GABA-A receptors — the most abundant inhibitory channels in the central nervous system. Anxiety relief traces to enhanced inhibition in the amygdala and prefrontal cortex, where dampened threat-related activity produces the subjective experience of calm. Sedation arises from potentiation in thalamocortical relay neurons and brainstem arousal centers, while memory suppression — which uniquely resists tolerance[16] — involves hippocampal receptors that modulate memory encoding.
Neuroadaptation
Chronic use triggers a cascade of changes that explain tolerance and dependence. GABA-A receptors are downregulated and physically removed from cell surfaces,[17][18] while the genes encoding key receptor components are transcriptionally repressed[19] and epigenetically silenced.[20]
When the drug is withdrawn, stress signaling surges — cortisol-releasing factor expression increases by over 300% within 24–48 hours[21] — driving the anxiety rebound effect, insomnia, and seizure risk that define benzodiazepine withdrawal. The rapid onset of this stress response reflects alprazolam's short half-life and the abrupt loss of inhibitory tone.
Why memory impairment resists tolerance while sedation does not remains unresolved — hippocampal receptor subtypes may undergo different adaptive trajectories than those mediating sedation.[16] Whether chronic therapeutic use causes lasting cognitive decline or dementia is suggested by epidemiological associations[22] and animal data showing hippocampal volume reduction,[23][24] but causation has not been established.
Subjective Effects[edit]
Alprazolam's experiential character is defined by a rapid, perceptible shift from baseline anxiety to emotional stillness — a transition fast enough to feel like a switch rather than a gradient. At lower doses, the effect is primarily anxiolytic: worry quiets, social friction eases, and physical tension dissolves. At higher doses, cognitive function narrows, speech slurs, inhibitions drop, and memory recording falters or ceases entirely. Set and setting strongly shape interpretation — the same dose in an anxious patient produces therapeutic calm, while in a non-anxious recreational user it tilts toward disinhibited euphoria.
Compared to clonazepam, alprazolam's effects are sharper in onset but shorter-lived, with more pronounced fluctuation between doses during chronic use. Relative to lorazepam, the profile is similar in character but alprazolam is generally reported as more euphoric at equivalent anxiolytic doses, consistent with its faster absorption.[5]
Effect Grid
At common doses, the full anxiolytic and sedative profile emerges. Anxiety is substantially reduced or eliminated. Emotional blunting becomes apparent — emotional responses are dampened, and distressing thoughts lose their urgency. Disinhibition increases, sometimes producing uncharacteristic social boldness or risk-taking. Cognitive slowing is noticeable: working memory and learning are impaired, and reaction times lengthen.
Sedation is moderate and dose-dependent, with peak effects occurring 30-60 minutes after oral ingestion. Muscle relaxation is prominent. Psychomotor performance is impaired at 1.25-2.5 hours post-dose, returning toward baseline by approximately 5 hours at 1 mg. Driving ability is significantly compromised.
Functional impairment is meaningful at this range. Complex tasks requiring sustained attention, memory encoding, or fine motor coordination should be avoided. Duration of impairment extends beyond subjective awareness of the drug's effects.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Physical fatigue · Dizziness · Dry mouth · Headache · Nausea · Appetite enhancement · Yawning · Nystagmus (eye wobbles) · Sexual arousal suppression · Constipation · Restlessness
Nausea · Appetite enhancement · Yawning · Nystagmus (eye wobbles) · Sexual arousal suppression · Constipation · Restlessness
Cognitive impairment · Language suppression · Motivation suppression · Cognitive fatigue · Focus suppression · Information processing suppression · Thought disorganization · Compulsive redosing urge · Confusion · Suggestibility enhancement · Amnesia
Cognitive fatigue · Focus suppression · Information processing suppression · Thought disorganization · Confusion · Suggestibility enhancement · Amnesia
Anxiety · Dysphoria · Emotional lability
Automaticity · Depersonalization · Derealization
Timeline
First perceptible effects emerge as a subtle reduction in background anxiety and a slight calming sensation. Most individuals notice a softening of tension before overt sedation appears.
Anxiolysis deepens steadily. Muscle relaxation becomes noticeable and a growing sense of calm or emotional detachment sets in. Mild sedation begins.
Maximum anxiolysis, sedation, and muscle relaxation. Cognitive impairment is at its highest — memory encoding is compromised and psychomotor performance measurably degraded. Emotional blunting and disinhibition are most pronounced.
Effects sustain at diminished intensity. Anxiolysis persists while sedation begins to lift. Cognitive impairment remains present but less intrusive.
Gradual return toward baseline. Residual sedation and mild cognitive slowing may persist. In dependent individuals, inter-dose anxiety rebound may emerge during this phase.
Subtle residual effects — mild grogginess, reduced emotional reactivity, and possible memory gaps for the peak period. Psychomotor impairment may persist beyond subjective awareness of drug effects.
⚠ Do not drive or operate machinery until at least 12 hours after ingestion, as measurable impairment outlasts perceived sobriety.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Severefatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- diazepam · clonazepam · lorazepam
Toxicity
Acute toxicity
Alprazolam has a wide therapeutic index when taken alone. No fatalities attributable solely to alprazolam overdose have been documented.[7][12] Overdose in isolation produces sedation, double vision, slurred speech, and poor coordination; deep coma from benzodiazepines alone is rare.[12]
No published LD50 data exist for alprazolam.safety citation needed
Polydrug toxicity
The principal acute danger is combination with other depressants. Co-ingestion with opioids produces additive or synergistic depression of breathing and consciousness — this is the leading cause of alprazolam-related death.[7] Alprazolam-related deaths increased by 233.8% between 2003 and 2009 in the United States, and benzodiazepines contributed to a five-fold increase in overdose deaths from 1999 to 2009.[7]
A fatal case documented blood alprazolam at only 0.04 mg/L — below the therapeutic range — demonstrating that synergistic respiratory depression can kill at subtherapeutic benzodiazepine levels.[8] Combination with alcohol is similarly dangerous: the interaction amplifies both drugs' effects on the brain, even though alcohol does not change how fast alprazolam is metabolized.[14] One case documented fatal brain damage from prolonged low oxygen during benzodiazepine-induced coma.[26]
Chronic toxicity
The brain is the primary organ of chronic toxicity. GABA-A changes underlie tolerance, while memory suppression persists with continued use and may not fully resolve after discontinuation.[16] Long-term use is associated with cognitive decline and potential dementia in large epidemiological studies,[22] and chronic use may reduce hippocampal volume.[23]
Liver toxicity is rare: one case of cholestatic jaundice with focal liver tissue death has been reported.[12] Urinary retention has been reported in overdose.[12]
Overdose management
Treatment is primarily supportive: airway protection, monitoring of breathing and heart rate, and clinical observation. Activated charcoal may be given if the person presents early. Do not induce vomiting. Flumazenil (a GABA-A receptor blocker) is reserved for severe breathing or cardiovascular compromise — it can trigger withdrawal seizures in dependent patients and must be used with extreme caution.[12]
Psychological risks
Alprazolam carries a distinctive adverse behavioral profile compared to older benzodiazepines. Three patterns are documented:
- PTSD worsening — alprazolam may intensify PTSD symptoms, a concern not reported at the same rate with other benzodiazepines[25]
- Increased impulsivity in borderline personality disorder — reported specifically with alprazolam[25]
- Mania or hypomania — more commonly triggered by alprazolam than by older benzodiazepines, representing a risk for people with bipolar spectrum conditions[25]
Cognitive impairment is dose-dependent: at 0.5 mg, visual attention is significantly affected; at 1.0 mg, working memory and learning are additionally impaired.[27] Even low-dose chronic use (0.5 mg/day for two weeks) produces measurable visual memory impairment.[28]
Tolerance develops unevenly — sedation and motor impairment tolerate, but memory impairment persists.[16] This creates a dangerous dissociation: patients feel functionally normal while remaining cognitively impaired.
Tolerance and dependence
Tolerance to sedation and motor effects develops rapidly — within days to weeks of continuous use. The underlying mechanism involves the brain reducing GABA-A receptor availability,[17] suppressing receptor gene expression,[19] making lasting chemical changes to gene regulation,[20] and physically removing receptors from cell surfaces.[18] A specific receptor subtype plays a critical role in sedative tolerance development,[29] and different subtypes contribute differently to tolerance versus dependence.[30]
Physical dependence can develop within days of continuous therapeutic-dose use. In animal studies, withdrawal symptoms including tremor, vomiting, and seizures appeared after only 9 days of daily dosing.[6] Alprazolam's short half-life (9–16 hours) means blood levels drop more sharply between doses than with longer-acting benzodiazepines, accelerating neuroadaptation.
Withdrawal is characterized by rebound effect anxiety, tremor, insomnia, and — in severe cases — seizures. The clinical presentation closely mimics the anxiety disorder that prompted treatment, making it difficult to distinguish withdrawal from relapse. One-third of panic disorder patients receiving long-term alprazolam could not discontinue during a three-week taper.[31]
Abrupt discontinuation in dependent patients risks life-threatening seizures. Gradual dose reduction is mandatory. Switching to a longer-acting benzodiazepine (chlordiazepoxide at approximately 86:1 ratio) followed by a 10%/day taper over 7–14 days has shown efficacy.[32] Adding cognitive behavioral therapy significantly improves the chances of successful discontinuation.[33]
Cross-tolerance exists with all benzodiazepines, barbiturates, Alcohol, zolpidem, and zopiclone.
Drug interactions
The most dangerous interactions arise from two independent mechanisms: drugs that amplify alprazolam's brain effects (pharmacodynamic synergism) and drugs that block its breakdown in the liver (pharmacokinetic inhibition).
Synergistic depressants
Combination with opioids (fentanyl, heroin, oxycodone, buprenorphine, methadone) produces additive or synergistic depression of breathing and consciousness — the principal cause of alprazolam-related fatality.[7][8] A fatal polydrug overdose has been documented with blood alprazolam at only 0.04 mg/L — below the therapeutic range.[8]
Combination with Alcohol is similarly dangerous through the same mechanism.[14]
CYP3A4 inhibitors
Because alprazolam is broken down almost exclusively by CYP3A4, drugs that block this enzyme can dramatically increase blood levels. Azole antifungals (itraconazole, ketoconazole) double alprazolam exposure.[34][35] Fluconazole becomes clinically significant at doses exceeding 200 mg/day.[35]
The antidepressants fluvoxamine and fluoxetine significantly slow alprazolam breakdown.[14] Certain antibiotics (clarithromycin, erythromycin), HIV medications (ritonavir), nefazodone, and grapefruit juice also inhibit CYP3A4.[36] Cimetidine and propoxyphene significantly impair clearance.[14]
CYP3A4 inducers
Rifampin decreases alprazolam exposure by 72–91%,[34] risking subtherapeutic levels and, in dependent patients, precipitated withdrawal.
Other notable interactions
Alprazolam may impair imipramine clearance.[14] In opioid-dependent populations, alprazolam reduces morphine withdrawal severity by suppressing noradrenergic stress signaling,[37] which may contribute to the high prevalence of benzodiazepine-opioid co-use.
No clinically significant interactions have been documented with propranolol, metronidazole, disulfiram, oral contraceptives, or alosetron.[14][38]
Contraindications
Absolute:
- Acute narrow-angle glaucoma — benzodiazepines may precipitate angle closure
- Known hypersensitivity to benzodiazepines
- Severe breathing problems — risk of respiratory depression, particularly with other depressants
- Sleep apnea — benzodiazepines reduce breathing drive and upper airway muscle tone
Relative:
- PTSD — alprazolam specifically may worsen symptoms[25]
- Borderline personality disorder — risk of increased impulsive behavior[25]
- Bipolar spectrum disorders — risk of triggering mania or hypomania[25]
- Severe liver disease — clearance markedly reduced, requiring substantial dose adjustment or avoidance[14]
- Elderly — reduced clearance and increased fall risk[14]
- Pregnancy — benzodiazepines cross the placenta and may cause neonatal complicationssafety citation needed
- Concurrent opioid use — synergistic respiratory depression; FDA black box warning applies[7]
Harm Reduction[edit]
Forms & Identification
Alprazolam circulates primarily as pharmaceutical tablets (0.25 mg, 0.5 mg, 1 mg, 2 mg) and counterfeit pressed pills. The structured data module above shows common forms and testing results. The critical concern is the prevalence of counterfeit "Xanax" tablets — pressed pills sold as alprazolam may contain no alprazolam at all, substituting other benzodiazepines (etizolam, flualprazolam, bromazolam) or fentanyl.
A reagent test cannot distinguish between benzodiazepine analogs. Fentanyl test strips should be used on any tablet of uncertain provenance, as fentanyl-adulterated counterfeit benzodiazepines have been directly implicated in overdose deaths.
Guidelines
- Test any tablet of uncertain origin with fentanyl test strips before use
- Start with the lowest available dose if tolerance is unknown or uncertain
- Do not redose based on perceived sobriety — memory suppression and judgment deficits may not be self-apparent
- Avoid driving or operating machinery for at least 8 hours after dosing
- Eat before dosing to moderate absorption speed
- Have a sober companion present, especially at higher doses
- If using regularly, do not stop abruptly — abrupt cessation after as few as 9 days of daily use can trigger withdrawal seizures
Set & Setting
Alprazolam's rapid onset means impairment can arrive faster than expected, particularly on an empty stomach. A familiar environment with trusted people reduces the risk of injury from falls, impaired coordination, or disinhibited behavior. Alprazolam impairs judgment before it impairs motor function — the user may feel capable while being demonstrably impaired.
Aftercare & integration. After alprazolam use, the primary aftercare concern is rebound effect anxiety — anxiety that returns at higher intensity than baseline once the drug wears off. This is a pharmacological effect, not a sign that the original anxiety has worsened. Adequate sleep, hydration, and avoidance of caffeine or stimulants in the 24 hours following use can moderate rebound symptoms.
If alprazolam was used to manage a panic episode, the period afterward is an opportunity to identify triggers and consider non-pharmacological strategies (breathing techniques, grounding exercises, therapy referral) for future episodes. Repeated use for acute anxiety episodes accelerates dependence formation.
Recovery & Support
Alprazolam dependence — even at prescribed doses — requires medical supervision for discontinuation. Abrupt cessation is dangerous. A prescribing clinician can design a gradual taper, often substituting a longer-acting benzodiazepine to smooth the withdrawal curve. Cognitive behavioral therapy significantly improves taper success rates.[33]
Support resources include the SAMHSA National Helpline (1-800-662-4357, free and confidential), the Benzodiazepine Information Coalition (benzoinfo.com), and peer support communities such as BenzoBuddies. Recovery from benzodiazepine dependence is often a months-long process — protracted withdrawal symptoms (anxiety, insomnia, sensory disturbances) can persist well beyond the acute phase and do not indicate treatment failure.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Unresponsiveness to voice or pain, slow or stopped breathing, blue or gray lips, seizures, or choking on vomit distinguish a medical emergency from heavy sedation. If the person cannot be roused by a firm sternal rub, they need help now.
Immediate steps:
- Call emergency services immediately
- Place the person in the recovery position (on their side) to prevent choking
- If opioid co-ingestion is suspected and naloxone is available, administer it — naloxone reverses opioid effects but will not reverse benzodiazepine sedation
- Do not induce vomiting
- Do not leave the person alone
- Monitor breathing continuously until help arrives
What to tell the dispatcher: The substance (alprazolam or "Xanax"), amount taken if known, time of ingestion, any other substances involved, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from drug-related prosecution.
Reversal agent: Flumazenil reverses benzodiazepine effects but is used only in hospital settings due to seizure risk in dependent individuals.
Legal Status[edit]
International framework
Alprazolam is listed under Schedule IV of the United Nations Convention on Psychotropic Substances, designating it as a substance with recognized therapeutic utility and lower abuse potential relative to higher schedules. Most national jurisdictions have implemented corresponding controlled substance classifications, though the degree of restriction varies significantly.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (Controlled Substances Act) | Prescription required; up to 5 refills per 6 months[3] |
| United Kingdom | Class C (Misuse of Drugs Act 1971) | Not available on NHS; private prescription only[3] |
| Canada | Schedule IV (Controlled Drugs and Substances Act) | Prescription required; unauthorized possession or trafficking is a criminal offence[39] |
| Australia | Schedule 8 (Therapeutic Goods Administration) | Reclassified February 2014; highest restriction for prescription medications; not recommended for panic disorder[3][9] |
| Germany | Anlage III (Narcotics Act) | Up to 1 mg: normal prescription; exceeding 1 mg: narcotic prescription form required[3] |
| Sweden | List IV (Narcotics Drugs Act 1968) | Controlled substance[3] |
| Netherlands | List 2 (Opium Law) | Available by prescription[3] |
Scheduling controversy
The Schedule IV classification in the United States has been a subject of ongoing debate. Alprazolam's rapid absorption, short half-life, and documented high dependence potential contrast with the low-abuse-potential designation implied by Schedule IV. Australia's 2014 decision to reclassify alprazolam to Schedule 8 — the most restrictive category for prescription medications — represents the most aggressive regulatory response to these concerns, based on evidence of tolerance, dependence, and widespread misuse.[9]
references
- [1] ^abSmith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. — Psychopharmacology PMID:6152055
- [2] ^abSanna E, Pau D, Tuveri F, et al. (1999) Molecular and neurochemical evaluation of the effects of etizolam on GABAA receptors under normal and stress conditions. — Arzneimittel-Forschung PMID:10083975
- [3]
- [4] ^Diaz L, Eiden C, Jouanjus E, et al. (2023) Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020. — Therapie doi:10.1016/j.therap.2023.02.002
- [5] ^abcMumford GK, Evans SM, Fleishaker JC, Griffiths RR (1995) Alprazolam absorption kinetics affects abuse liability. — Clinical pharmacology and therapeutics PMID:7697954
- [6] ^abMartin JR, Moreau JL, Jenck F (1995) Precipitated withdrawal in squirrel monkeys after repeated daily oral administration of alprazolam, diazepam, flunitrazepam or oxazepam. — Psychopharmacology PMID:7617819